Lexaria Bioscience Corp.
LEXX
$1.35
-$0.34-20.12%
NASDAQ
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Net Income | -9.38M | -7.32M | -5.80M | -4.85M | -5.44M |
| Total Depreciation and Amortization | 95.80K | 109.10K | 108.80K | 165.60K | 179.30K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 791.90K | 634.40K | 621.00K | 777.70K | 430.20K |
| Change in Net Operating Assets | 1.11M | 72.80K | 106.50K | -782.50K | -378.80K |
| Cash from Operations | -7.38M | -6.50M | -4.96M | -4.69M | -5.21M |
| Capital Expenditure | -67.60K | -67.60K | -43.00K | 0.00 | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -89.70K | -118.80K | -145.60K | -187.40K | -199.00K |
| Cash from Investing | -157.30K | -186.40K | -188.60K | -187.40K | -199.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 9.40M | 12.84M | 10.32M | 10.32M | 6.98M |
| Repurchase of Common Stock | -- | -- | -- | -121.70K | -121.70K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 9.40M | 12.84M | 10.32M | 10.19M | 6.86M |
| Foreign Exchange rate Adjustments | -97.60K | -27.30K | -19.70K | -21.80K | -20.60K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.76M | 6.12M | 5.15M | 5.30M | 1.43M |